{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:10:36Z","timestamp":1779358236733,"version":"3.51.4"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T00:00:00Z","timestamp":1555027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00508-019-1454-0","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T10:03:08Z","timestamp":1555063388000},"page":"16-26","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Andere spezifische Diabetesformen und exokrine Pankreasinsuffizienz (Update 2019)","Other specific types of diabetes and exocrine pancreatic insufficiency (Update 2019)"],"prefix":"10.1007","volume":"131","author":[{"given":"Susanne","family":"Kaser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Winhofer-St\u00f6ckl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Kazemi-Shirazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine E.","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Brath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Sourij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greisa","family":"Vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidemarie","family":"Abrahamian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimund","family":"Weitgasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Resl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Clodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Luger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,12]]},"reference":[{"issue":"5","key":"1454_CR1","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","volume":"93","author":"LK Nieman","year":"2008","unstructured":"Nieman LK, et\u00a0al. The diagnosis of Cushing\u2019s syndrome: an Endocrine Society Clinical Practice Guideline. J\u00a0Clin Endocrinol Metab. 2008;93(5):1526\u201340.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1454_CR2","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"Nieman LK, et\u00a0al. Treatment of Cushing\u2019s Syndrome: An Endocrine Society Clinical Practice Guideline. J\u00a0Clin Endocrinol Metab. 2015;100(8):2807\u201331.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1454_CR3","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, et\u00a0al. Acromegaly: an endocrine society clinical practice guideline. J\u00a0Clin Endocrinol Metab. 2014;99(11):3933\u201351.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1454_CR4","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.tem.2016.04.014","volume":"27","author":"S Frara","year":"2016","unstructured":"Frara S, et\u00a0al. Current and Emerging Aspects of Diabetes Mellitus in Acromegaly. Trends Endocrinol Metab. 2016;27(7):470\u201383.","journal-title":"Trends Endocrinol Metab"},{"key":"1454_CR5","unstructured":"Abrahamian, H. et\u00a0al. (2016) [Mental disorders and diabetes mellitus]. Wien Klin Wochenschr 128 [Suppl 2]:S170\u2013S178."},{"issue":"12","key":"1454_CR6","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/dom.12739","volume":"18","author":"S Breakey","year":"2016","unstructured":"Breakey S, et al. Glucocorticoid-induced hyperglycaemia in respiratory disease: a\u00a0systematic review and meta-analysis. Diabetes Obes Metab. 2016;18(12):1274\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1454_CR7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.diabres.2015.02.010","volume":"108","author":"T Katsuyama","year":"2015","unstructured":"Katsuyama T, et al. Risk factors for the development of glucocorticoid-induced diabetes mellitus. Diabetes Res Clin Pract. 2015;108(2):273\u20139.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"1454_CR8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1262-3636(06)72809-9","volume":"32","author":"A. Penfornis","year":"2006","unstructured":"Penfornis, A. and Kury-Paulin, S. (2006) Immunosuppressive drug-induced diabetes. Diabetes Metab 32 (5 Pt 2), 539\u201346.","journal-title":"Diabetes & Metabolism"},{"issue":"2","key":"1454_CR9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2362.2008.02067.x","volume":"39","author":"DH Raalte van","year":"2009","unstructured":"van Raalte DH, et al. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest. 2009;39(2):81\u201393.","journal-title":"Eur J Clin Invest"},{"issue":"9","key":"1454_CR10","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.2337\/dc12-2441","volume":"36","author":"M Hecking","year":"2013","unstructured":"Hecking M, et\u00a0al. Glucose metabolism after renal transplantation. Diabetes Care. 2013;36(9):2763\u201371.","journal-title":"Diabetes Care"},{"issue":"9","key":"1454_CR11","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1097\/TP.0b013e3181d2fec1","volume":"89","author":"HT Kuo","year":"2010","unstructured":"Kuo HT, et al. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network\/United Network for Organ Sharing database. Transplantation. 2010;89(9):1134\u201340.","journal-title":"Transplantation"},{"issue":"4","key":"1454_CR12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jiac.2016.01.007","volume":"22","author":"K Schulte-Hermann","year":"2016","unstructured":"Schulte-Hermann K, et al. Impaired lipid profile and insulin resistance in a\u00a0cohort of Austrian HIV patients. J\u00a0Infect Chemother. 2016;22(4):248\u201353.","journal-title":"J Infect Chemother"},{"issue":"1","key":"1454_CR13","first-page":"1","volume":"9","author":"A Cheema","year":"2018","unstructured":"Cheema A, et\u00a0al. Autoimmune Diabetes Associated With Pembrolizumab: A Review of Published Case Reports. World. J\u00a0Oncol. 2018;9(1):1\u20134.","journal-title":"J Oncol"},{"issue":"5","key":"1454_CR14","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/CMR.0000000000000384","volume":"27","author":"A Tsiogka","year":"2017","unstructured":"Tsiogka A, et\u00a0al. Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma. Melanoma Res. 2017;27(5):524\u20135.","journal-title":"Melanoma Res"},{"key":"1454_CR15","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-18-0021","author":"S Lee","year":"2018","unstructured":"Lee S, et al. Rapid-onset diabetic ketoacidosis secondary to nivolumab therapy. Endocrinol Diabetes Metab Case Rep. 2018. \n                    https:\/\/doi.org\/10.1530\/EDM-18-0021\n                    \n                  .","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"9557","key":"1454_CR16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","volume":"369","author":"WJ Elliott","year":"2007","unstructured":"Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a\u00a0network meta-analysis. Lancet. 2007;369(9557):201\u20137.","journal-title":"Lancet"},{"issue":"9716","key":"1454_CR17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"N Sattar","year":"2010","unstructured":"Sattar N, et al. Statins and risk of incident diabetes: a\u00a0collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735\u201342.","journal-title":"Lancet"},{"issue":"170","key":"1454_CR18","first-page":"339","volume":"43","author":"RB Tattersall","year":"1974","unstructured":"Tattersall RB. Mild familial diabetes with dominant inheritance. Q\u00a0J Med. 1974;43(170):339\u201357.","journal-title":"Q J Med"},{"issue":"1","key":"1454_CR19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2337\/diab.24.1.44","volume":"24","author":"RB Tattersall","year":"1975","unstructured":"Tattersall RB, Fajans SS. A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes. 1975;24(1):44\u201353.","journal-title":"Diabetes"},{"issue":"4","key":"1454_CR20","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s00125-008-0942-y","volume":"51","author":"S Ellard","year":"2008","unstructured":"Ellard S, et al. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia. 2008;51(4):546\u201353.","journal-title":"Diabetologia"},{"key":"1454_CR21","series-title":"Pt","first-page":"403","volume-title":"Maturity onset diabetes of the young: identification and diagnosis. Ann Clin Biochem 50","author":"TJ McDonald","year":"2013","unstructured":"McDonald TJ, Ellard S. Maturity onset diabetes of the young: identification and diagnosis. Ann Clin Biochem 50. Pt, Bd. 5. 2013. S.\u00a0403\u201315."},{"issue":"3","key":"1454_CR22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/ann.34.3.207.217","volume":"34","author":"A Stride","year":"2002","unstructured":"Stride A, Hattersley AT. Different genes, different diabetes: lessons from maturity-onset diabetes of the young. Ann Med. 2002;34(3):207\u201316.","journal-title":"Ann Med"},{"issue":"7","key":"1454_CR23","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2337\/dc07-2017","volume":"31","author":"D Martin","year":"2008","unstructured":"Martin D, et al. Long-term follow-up of oral glucose tolerance test-derived glucose tolerance and insulin secretion and insulin sensitivity indexes in subjects with glucokinase mutations (MODY2). Diabetes Care. 2008;31(7):1321\u20133.","journal-title":"Diabetes Care"},{"key":"1454_CR24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/DMSO.S23353","volume":"5","author":"DS Gardner","year":"2012","unstructured":"Gardner DS, Tai ES. Clinical features and treatment of maturity onset diabetes of the young (MODY). Diabetes Metab Syndr Obes. 2012;5:101\u20138.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"7","key":"1454_CR25","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s00431-006-0106-3","volume":"165","author":"E Feigerlova","year":"2006","unstructured":"Feigerlova E, et\u00a0al. Aetiological heterogeneity of asymptomatic hyperglycaemia in children and adolescents. Eur J Pediatr. 2006;165(7):446\u201352.","journal-title":"Eur J Pediatr"},{"issue":"2","key":"1454_CR26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s001250050666","volume":"40","author":"G Velho","year":"1997","unstructured":"Velho G, et al. Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia. 1997;40(2):217\u201324.","journal-title":"Diabetologia"},{"issue":"1","key":"1454_CR27","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1067\/mob.2001.113127","volume":"185","author":"G Spyer","year":"2001","unstructured":"Spyer G, et\u00a0al. Influence of maternal and fetal glucokinase mutations in gestational diabetes. Am J Obstet Gynecol. 2001;185(1):240\u20131.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"1454_CR28","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/953","volume":"19","author":"AT Hattersley","year":"1998","unstructured":"Hattersley AT, et\u00a0al. Mutations in the glucokinase gene of the fetus result in reduced birth weight. Nat Genet. 1998;19(3):268\u201370.","journal-title":"Nat Genet"},{"issue":"7","key":"1454_CR29","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2337\/diacare.28.7.1751","volume":"28","author":"A Stride","year":"2005","unstructured":"Stride A, et al. Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers. Diabetes Care. 2005;28(7):1751\u20136.","journal-title":"Diabetes Care"},{"issue":"9392","key":"1454_CR30","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(03)14571-0","volume":"362","author":"ER Pearson","year":"2003","unstructured":"Pearson ER, et\u00a0al. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet. 2003;362(9392):1275\u201381.","journal-title":"Lancet"},{"issue":"5","key":"1454_CR31","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s00125-005-1738-y","volume":"48","author":"ER Pearson","year":"2005","unstructured":"Pearson ER, et\u00a0al. Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha mutations in a\u00a0large European collection. Diabetologia. 2005;48(5):878\u201385.","journal-title":"Diabetologia"},{"issue":"4","key":"1454_CR32","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1371\/journal.pmed.0040118","volume":"4","author":"ER Pearson","year":"2007","unstructured":"Pearson ER, et\u00a0al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. Plos Med. 2007;4(4):e118.","journal-title":"Plos Med"},{"issue":"12","key":"1454_CR33","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1464-5491.2006.01999.x","volume":"23","author":"EL Edghill","year":"2006","unstructured":"Edghill EL, et al. Hepatocyte nuclear factor-1 beta mutations cause neonatal diabetes and intrauterine growth retardation: support for a\u00a0critical role of HNF-1beta in human pancreatic development. Diabet Med. 2006;23(12):1301\u20136.","journal-title":"Diabet Med"},{"issue":"13","key":"1454_CR34","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMra002168","volume":"345","author":"SS Fajans","year":"2001","unstructured":"Fajans SS, et al. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N\u00a0Engl J Med. 2001;345(13):971\u201380.","journal-title":"N Engl J Med"},{"key":"1454_CR35","doi-asserted-by":"crossref","unstructured":"American Diabetes, A. (2014) Standards of medical care in diabetes\u20142014. Diabetes Care 37 Suppl 1, S14\u201380.","DOI":"10.2337\/dc14-S014"},{"key":"1454_CR36","unstructured":"American Diabetes, A. (2018) 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care 41 (Suppl 1), S13\u2013S27."},{"issue":"5","key":"1454_CR37","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00431-015-2675-5","volume":"175","author":"C Reinauer","year":"2016","unstructured":"Reinauer C, et\u00a0al. Low prevalence of patients with mitochondrial disease in the German\/Austrian DPV diabetes registry. Eur J Pediatr. 2016;175(5):613\u201322.","journal-title":"Eur J Pediatr"},{"issue":"10","key":"1454_CR38","first-page":"460","volume":"70","author":"HM Wit de","year":"2012","unstructured":"de Wit HM, et al. MIDD or MELAS : that\u2019s not the question MIDD evolving into MELAS : a\u00a0severe phenotype of the m.3243A\u3009G mutation due to paternal co-inheritance of type 2 diabetes and a\u00a0high heteroplasmy level. Neth J Med. 2012;70(10):460\u20132.","journal-title":"Neth J Med"},{"key":"1454_CR39","unstructured":"Tuomi T, et\u00a0al. Atypical Forms of. Diabetes Endotext (de Groot Lj Et Al Eds). 2000. PMID: 25905351."},{"issue":"1-2","key":"1454_CR40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2015.06.004","volume":"116","author":"Ayman W. El-Hattab","year":"2015","unstructured":"El-Hattab, A.W. et\u00a0al. (2015) MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab 116 (1-2), 4\u201312.","journal-title":"Molecular Genetics and Metabolism"},{"issue":"3","key":"1454_CR41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11154-010-9150-4","volume":"11","author":"IK Temple","year":"2010","unstructured":"Temple IK, Shield JP. 6q24 transient neonatal diabetes. Rev Endocr Metab Disord. 2010;11(3):199\u2013204.","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"1454_CR42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1399-5448.2009.00530.x","volume":"11","author":"B Wiedemann","year":"2010","unstructured":"Wiedemann B, et al. Incidence of neonatal diabetes in Austria-calculation based on the Austrian Diabetes Register. Pediatr Diabetes. 2010;11(1):18\u201323.","journal-title":"Pediatr Diabetes"},{"issue":"6","key":"1454_CR43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11892-011-0234-7","volume":"11","author":"SA Greeley","year":"2011","unstructured":"Greeley SA, et\u00a0al. Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment. Curr Diab Rep. 2011;11(6):519\u201332.","journal-title":"Curr Diab Rep"},{"issue":"5","key":"1454_CR44","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1056\/NEJMoa055068","volume":"355","author":"AP Babenko","year":"2006","unstructured":"Babenko AP, et\u00a0al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N\u00a0Engl J Med. 2006;355(5):456\u201366.","journal-title":"N Engl J Med"},{"issue":"3","key":"1454_CR45","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000329188","volume":"11","author":"Y Cui","year":"2011","unstructured":"Cui Y, Andersen DK. Pancreatogenic diabetes: special considerations for management. Pancreatology. 2011;11(3):279\u201394.","journal-title":"Pancreatology"},{"issue":"4","key":"1454_CR46","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/dmrr.2260","volume":"28","author":"N Ewald","year":"2012","unstructured":"Ewald N, et\u00a0al. Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev. 2012;28(4):338\u201342.","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"1454_CR47","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2337\/db16-1477","volume":"66","author":"DK Andersen","year":"2017","unstructured":"Andersen DK, et\u00a0al. Pancreatogenic Diabetes, and Pancreatic Cancer. Diabetes. Diabetes. 2017;66(5):1103\u201310.","journal-title":"Diabetes"},{"issue":"4","key":"1454_CR48","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s002680020337","volume":"25","author":"LA Slezak","year":"2001","unstructured":"Slezak LA, Andersen DK. Pancreatic resection: effects on glucose metabolism. World J Surg. 2001;25(4):452\u201360.","journal-title":"World J Surg"},{"issue":"3","key":"1454_CR49","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejim.2012.12.017","volume":"24","author":"N Ewald","year":"2013","unstructured":"Ewald N, Bretzel RG. Diabetes mellitus secondary to pancreatic diseases (Type 3c)\u2014are we neglecting an important disease? Eur J Intern Med. 2013;24(3):203\u20136.","journal-title":"Eur J Intern Med"},{"issue":"42","key":"1454_CR50","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.3748\/wjg.v19.i42.7276","volume":"19","author":"N Ewald","year":"2013","unstructured":"Ewald N, Hardt PD. Diagnosis and treatment of diabetes mellitus in chronic pancreatitis. World J Gastroenterol. 2013;19(42):7276\u201381.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"1454_CR51","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","volume":"32","author":"A Moran","year":"2009","unstructured":"Moran A, et al. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009;32(9):1626\u201331.","journal-title":"Diabetes Care"},{"issue":"4","key":"1454_CR52","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jcf.2013.02.008","volume":"12","author":"A Kelly","year":"2013","unstructured":"Kelly A, Moran A. Update on cystic fibrosis-related diabetes. J\u00a0Cyst Fibros. 2013;12(4):318\u201331.","journal-title":"J Cyst Fibros"},{"issue":"6","key":"1454_CR53","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jcf.2016.04.004","volume":"15","author":"V Boudreau","year":"2016","unstructured":"Boudreau V, et\u00a0al. Variation of glucose tolerance in adult patients with cystic fibrosis: What is the potential contribution of insulin sensitivity? J\u00a0Cyst Fibros. 2016;15(6):839\u201345.","journal-title":"J Cyst Fibros"},{"issue":"9","key":"1454_CR54","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2337\/diacare.28.9.2141","volume":"28","author":"CE Milla","year":"2005","unstructured":"Milla CE, et\u00a0al. Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care. 2005;28(9):2141\u20134.","journal-title":"Diabetes Care"},{"issue":"2","key":"1454_CR55","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1164\/rccm.201403-0576OC","volume":"191","author":"C Lewis","year":"2015","unstructured":"Lewis C, et al. Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex. Am J Respir Crit Care Med. 2015;191(2):194\u2013200.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"1454_CR56","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","volume":"33","author":"A Moran","year":"2010","unstructured":"Moran A, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a\u00a0position statement of the American Diabetes Association and a\u00a0clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697\u2013708.","journal-title":"Diabetes Care"},{"issue":"4","key":"1454_CR57","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/pedi.12014","volume":"14","author":"M Sunni","year":"2013","unstructured":"Sunni M, et\u00a0al. Exogenous insulin requirements do not differ between youth and adults with cystic fibrosis related diabetes. Pediatr Diabetes. 2013;14(4):295\u20138.","journal-title":"Pediatr Diabetes"},{"issue":"4","key":"1454_CR58","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3390\/nu4040286","volume":"4","author":"BW Balzer","year":"2012","unstructured":"Balzer BW, et\u00a0al. Low glycaemic index dietary interventions in youth with cystic fibrosis: a\u00a0systematic review and discussion of the clinical implications. Nutrients. 2012;4(4):286\u201396.","journal-title":"Nutrients"},{"issue":"1","key":"1454_CR59","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000049445","volume":"2","author":"PD Hardt","year":"2002","unstructured":"Hardt PD, et al. Chronic pancreatitis and diabetes mellitus. A retrospective analysis of 156 ERCP investigations in patients with insulin-dependent and non-insulin-dependent diabetes mellitus. Pancreatology. 2002;2(1):30\u20133.","journal-title":"Pancreatology"},{"issue":"9","key":"1454_CR60","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1023\/A:1025422423435","volume":"48","author":"PD Hardt","year":"2003","unstructured":"Hardt PD, et\u00a0al. High prevalence of steatorrhea in 101 diabetic patients likely to suffer from exocrine pancreatic insufficiency according to low fecal elastase 1 concentrations: a\u00a0prospective multicenter study. Dig Dis Sci. 2003;48(9):1688\u201392.","journal-title":"Dig Dis Sci"},{"issue":"10","key":"1454_CR61","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1055\/s-2001-17867","volume":"39","author":"A Icks","year":"2001","unstructured":"Icks A, et al. Low fecal elastase-1 in type I diabetes mellitus. Z\u00a0Gastroenterol. 2001;39(10):823\u201330.","journal-title":"Z Gastroenterol"},{"issue":"3","key":"1454_CR62","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000198833","volume":"25","author":"PG Lankisch","year":"1982","unstructured":"Lankisch PG, et al. Exocrine pancreatic function in insulin-dependent diabetes mellitus. Digestion. 1982;25(3):211\u20136.","journal-title":"Digestion"},{"key":"1454_CR63","doi-asserted-by":"crossref","first-page":"595649","DOI":"10.1155\/2015\/595649","volume":"2015","author":"M Piciucchi","year":"2015","unstructured":"Piciucchi M, et\u00a0al. Exocrine pancreatic insufficiency in diabetic patients: prevalence, mechanisms, and treatment. Int J Endocrinol. 2015;2015:595649.","journal-title":"Int J Endocrinol"},{"issue":"16","key":"1454_CR64","first-page":"388","volume":"39","author":"G Bretzke","year":"1984","unstructured":"Bretzke G. Diabetes mellitus and exocrine pancreas function. Z\u00a0Gesamte Inn Med. 1984;39(16):388\u201390.","journal-title":"Z Gesamte Inn Med"},{"issue":"10","key":"1454_CR65","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1080\/003655201750422657","volume":"36","author":"W Rathmann","year":"2001","unstructured":"Rathmann W, et\u00a0al. Low faecal elastase 1 concentrations in type 2 diabetes mellitus. Scand J Gastroenterol. 2001;36(10):1056\u201361.","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"1454_CR66","doi-asserted-by":"crossref","first-page":"e0179911","DOI":"10.1371\/journal.pone.0179911","volume":"12","author":"M Lundberg","year":"2017","unstructured":"Lundberg M, et\u00a0al. The density of parasympathetic axons is reduced in the exocrine pancreas of individuals recently diagnosed with type 1 diabetes. PLoS ONE. 2017;12(6):e179911.","journal-title":"PLoS ONE"},{"issue":"10","key":"1454_CR67","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1089\/ars.2011.4079","volume":"15","author":"M Apte","year":"2011","unstructured":"Apte M, et\u00a0al. The fibrosis of chronic pancreatitis: new insights into the role of pancreatic stellate cells. Antioxid Redox Signal. 2011;15(10):2711\u201322.","journal-title":"Antioxid Redox Signal"},{"issue":"4","key":"1454_CR68","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1559-4572.2008.00024.x","volume":"3","author":"MR Hayden","year":"2008","unstructured":"Hayden MR, et al. Attenuation of endocrine-exocrine pancreatic communication in type 2 diabetes: pancreatic extracellular matrix ultrastructural abnormalities. J\u00a0Cardiometab Syndr. 2008;3(4):234\u201343.","journal-title":"J Cardiometab Syndr"},{"issue":"7","key":"1454_CR69","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/MPA.0b013e31821fde3f","volume":"40","author":"D Wu","year":"2011","unstructured":"Wu D, et\u00a0al. Endocrine pancreatic function changes after acute pancreatitis. Pancreas. 2011;40(7):1006\u201311.","journal-title":"Pancreas"},{"issue":"9","key":"1454_CR70","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/ajg.2017.181","volume":"112","author":"MD Bellin","year":"2017","unstructured":"Bellin MD, et\u00a0al. Patient and Disease Characteristics Associated With the Presence of Diabetes Mellitus in Adults With Chronic Pancreatitis in the United States. Am J Gastroenterol. 2017;112(9):1457\u201365.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"1454_CR71","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/2050640616684695","volume":"5","author":"JM Lohr","year":"2017","unstructured":"Lohr JM, et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United Eur Gastroenterol\u00a0J. 2017;5(2):153\u201399.","journal-title":"United Eur Gastroenterol J"},{"issue":"8","key":"1454_CR72","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1097\/MCG.0000000000000917","volume":"52","author":"D Iglesia-Garcia de la","year":"2018","unstructured":"Iglesia-Garcia D de la, et al. Increased Risk of Mortality Associated With Pancreatic Exocrine Insufficiency in Patients With Chronic Pancreatitis. J\u00a0Clin Gastroenterol. 2018; 52(8):e63\u2013e72. \n                    https:\/\/doi.org\/10.1097\/MCG.0000000000000917\n                    \n                  .","journal-title":"Pancreatitis. J\u00a0Clin Gastroenterol."},{"issue":"1","key":"1454_CR73","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MPG.0b013e31820e208e","volume":"53","author":"E Vijver Van de","year":"2011","unstructured":"Van de Vijver E, et al. Treatment of infants and toddlers with cystic fibrosis-related pancreatic insufficiency and fat malabsorption with pancrelipase MT. J\u00a0Pediatr Gastroenterol Nutr. 2011;53(1):61\u20134.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"1454_CR74","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.pan.2017.09.004","volume":"17","author":"G Roeyen","year":"2017","unstructured":"Roeyen G, et al. The impact of pancreaticoduodenectomy on endocrine and exocrine pancreatic function: A prospective cohort study based on pre- and postoperative function tests. Pancreatology. 2017;17(6):974\u201382.","journal-title":"Pancreatology"},{"key":"1454_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/nu9111241","author":"M Vujasinovic","year":"2017","unstructured":"Vujasinovic M, et\u00a0al. Pancreatic Exocrine Insufficiency after Bariatric Surgery. Nutrients. 2017. \n                    https:\/\/doi.org\/10.3390\/nu9111241\n                    \n                  .","journal-title":"Nutrients"},{"issue":"5","key":"1454_CR76","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/joim.12745","volume":"283","author":"JM Lohr","year":"2018","unstructured":"Lohr JM, et\u00a0al. The ageing pancreas: a\u00a0systematic review of the evidence and analysis of the consequences. J\u00a0Intern Med. 2018;283(5):446\u201360.","journal-title":"J Intern Med"},{"issue":"5","key":"1454_CR77","first-page":"867","volume":"92","author":"CE Moran","year":"1997","unstructured":"Moran CE, et\u00a0al. Bone mineral density in patients with pancreatic insufficiency and steatorrhea. Am J Gastroenterol. 1997;92(5):867\u201371.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"1454_CR78","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.pan.2013.02.008","volume":"13","author":"EC Sikkens","year":"2013","unstructured":"Sikkens EC, et al. The prevalence of fat-soluble vitamin deficiencies and a\u00a0decreased bone mass in patients with chronic pancreatitis. Pancreatology. 2013;13(3):238\u201342.","journal-title":"Pancreatology"},{"issue":"8","key":"1454_CR79","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5694\/j.1326-5377.2010.tb04000.x","volume":"193","author":"J Toouli","year":"2010","unstructured":"Toouli J, et\u00a0al. Management of pancreatic exocrine insufficiency: Australasian Pancreatic Club recommendations. Med J Aust. 2010;193(8):461\u20137.","journal-title":"Med J Aust"},{"issue":"3","key":"1454_CR80","first-page":"187","volume":"35","author":"C Loser","year":"1997","unstructured":"Loser C, et al. 13C-starch breath test\u2014comparative clinical evaluation of an indirect pancreatic function test. Z\u00a0Gastroenterol. 1997;35(3):187\u201394.","journal-title":"Z Gastroenterol"},{"issue":"3","key":"1454_CR81","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2337\/diacare.29.03.06.dc05-1389","volume":"29","author":"F Cavalot","year":"2006","unstructured":"Cavalot F, et al. Does pancreatic elastase-1 in stools predict steatorrhea in type 1 diabetes? Diabetes Care. 2006;29(3):719\u201321.","journal-title":"Diabetes Care"},{"issue":"3","key":"1454_CR82","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/BF00275269","volume":"19","author":"R Ebert","year":"1980","unstructured":"Ebert R, Creutzfeldt W. Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution. Diabetologia. 1980;19(3):198\u2013204.","journal-title":"Diabetologia"},{"key":"1454_CR83","doi-asserted-by":"crossref","unstructured":"Ewald, N. et\u00a0al. (2009) Determinants of Exocrine Pancreatic Function as Measured by Fecal Elastase-1 Concentrations (FEC) in Patients with Diabetes mellitus. Eur J Med Res 14 (3), 118\u201322.","DOI":"10.1186\/2047-783X-14-3-118"},{"issue":"5","key":"1454_CR84","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1159\/000073655","volume":"3","author":"PD Hardt","year":"2003","unstructured":"Hardt PD, et\u00a0al. High prevalence of exocrine pancreatic insufficiency in diabetes mellitus. A multicenter study screening fecal elastase 1 concentrations in 1,021 diabetic patients. Pancreatology. 2003;3(5):395\u2013402.","journal-title":"Pancreatology"},{"issue":"12","key":"1454_CR85","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1111\/j.1572-0241.2003.08730.x","volume":"98","author":"AC Nunes","year":"2003","unstructured":"Nunes AC, et\u00a0al. Screening for pancreatic exocrine insufficiency in patients with diabetes mellitus. Am J Gastroenterol. 2003;98(12):2672\u20135.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"1454_CR86","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.pan.2018.02.010","volume":"18","author":"HM Ni Chonchubhair","year":"2018","unstructured":"Ni Chonchubhair HM, et al. The prevalence of small intestinal bacterial overgrowth in non-surgical patients with chronic pancreatitis and pancreatic exocrine insufficiency (PEI). Pancreatology. 2018;18(4):379\u2013385. \n                    https:\/\/doi.org\/10.1016\/j.pan.2018.02.010\n                    \n                  .","journal-title":"Pancreatology"},{"issue":"3","key":"1454_CR87","doi-asserted-by":"crossref","first-page":"G632","DOI":"10.1152\/ajpgi.1997.272.3.G632","volume":"272","author":"J. Keller","year":"1997","unstructured":"Keller, J. et\u00a0al. (1997) Duodenal and ileal nutrient deliveries regulate human intestinal motor and pancreatic responses to a\u00a0meal. Am J Physiol 272 (3 Pt 1), G632\u20137.","journal-title":"American Journal of Physiology-Gastrointestinal and Liver Physiology"},{"issue":"5","key":"1454_CR88","first-page":"1624","volume":"112","author":"P Layer","year":"1997","unstructured":"Layer P, et\u00a0al. Altered postprandial motility in chronic pancreatitis: role of malabsorption. Baillieres Clin Gastroenterol. 1997;112(5):1624\u201334.","journal-title":"Baillieres Clin Gastroenterol"},{"issue":"7","key":"1454_CR89","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nrgastro.2011.91","volume":"8","author":"JS Leeds","year":"2011","unstructured":"Leeds JS, et al. The role of fecal elastase-1 in detecting exocrine pancreatic disease. Nat Rev Gastroenterol Hepatol. 2011;8(7):405\u201315.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"1454_CR90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/v10039-011-0005-3","volume":"56","author":"JE Dominguez-Munoz","year":"2011","unstructured":"Dominguez-Munoz JE. Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency: when is it indicated, what is the goal and how to do it? Adv Med Sci. 2011;56(1):1\u20135.","journal-title":"Adv Med Sci"},{"issue":"7","key":"1454_CR91","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.cgh.2011.02.027","volume":"9","author":"JE Dominguez-Munoz","year":"2011","unstructured":"Dominguez-Munoz JE. Chronic pancreatitis and persistent steatorrhea: what is the correct dose of enzymes? Clin Gastroenterol Hepatol. 2011;9(7):541\u20136.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"1454_CR92","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/j.1365-2036.2011.04631.x","volume":"33","author":"N. Gubergrits","year":"2011","unstructured":"Gubergrits, N. et\u00a0al. (2011) A 6\u2011month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery. Aliment Pharmacol Ther 33 (10), 1152\u201361.","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"3","key":"1454_CR93","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bpg.2010.03.006","volume":"24","author":"EC Sikkens","year":"2010","unstructured":"Sikkens EC, et\u00a0al. Pancreatic enzyme replacement therapy in chronic pancreatitis. Best Pract Res Clin Gastroenterol. 2010;24(3):337\u201347.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"8","key":"1454_CR94","first-page":"1354","volume":"66","author":"D Iglesia-Garcia de la","year":"2017","unstructured":"de la Iglesia-Garcia D, et al. Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis. Gut. 2017;66(8):1354\u20135.","journal-title":"Gut"},{"issue":"2","key":"1454_CR95","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/MPA.0000000000000721","volume":"46","author":"KL Raphael","year":"2017","unstructured":"Raphael KL, et al. Pancreatic Insufficiency Secondary to Tobacco Exposure: A Controlled Cross-Sectional Evaluation. Pancreas. 2017;46(2):237\u201343.","journal-title":"Pancreas"},{"issue":"7","key":"1454_CR96","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/qjmed\/hcl059","volume":"99","author":"PA Sarafidis","year":"2006","unstructured":"Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006;99(7):431\u20136.","journal-title":"QJM"},{"issue":"16","key":"1454_CR97","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.286.16.1945","volume":"286","author":"B Luna","year":"2001","unstructured":"Luna B, Feinglos MN. Drug-induced hyperglycemia. JAMA. 2001;286(16):1945\u20138.","journal-title":"JAMA"},{"key":"1454_CR98","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.1097\/CCM.0b013e3181dda0f2","volume":"38","author":"Zachariah Thomas","year":"2010","unstructured":"Thomas, Z. et\u00a0al. (2010) Drug-induced endocrine disorders in the intensive care unit. Crit Care Med 38 (6 Suppl), S219\u201330.","journal-title":"Critical Care Medicine"},{"issue":"2","key":"1454_CR99","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bcp.2014.01.020","volume":"88","author":"A Fuhrmann","year":"2014","unstructured":"Fuhrmann A, et\u00a0al. Molecular mechanisms underlying the effects of cyclosporin A and sirolimus on glucose and lipid metabolism in liver, skeletal muscle and adipose tissue in an in vivo rat model. Biochem Pharmacol. 2014;88(2):216\u201328.","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"1454_CR100","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.diabet.2017.05.003","volume":"43","author":"B Verges","year":"2017","unstructured":"Verges B. Effects of anti-somatostatin agents on glucose metabolism. Diabetes Metab. 2017;43(5):411\u20135.","journal-title":"Diabetes Metab"},{"issue":"1","key":"1454_CR101","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2010.01.040","volume":"53","author":"KD Watt","year":"2010","unstructured":"Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: a\u00a0review and guide to management. J\u00a0Hepatol. 2010;53(1):199\u2013206.","journal-title":"J Hepatol"},{"issue":"2","key":"1454_CR102","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","volume":"8","author":"M Hert De","year":"2011","unstructured":"De Hert M, et\u00a0al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114\u201326.","journal-title":"Nat Rev Endocrinol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-019-1454-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-019-1454-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-019-1454-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T23:21:30Z","timestamp":1586560890000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-019-1454-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,12]]},"references-count":102,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["1454"],"URL":"https:\/\/doi.org\/10.1007\/s00508-019-1454-0","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,12]]},"assertion":[{"value":"12 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.\u00a0Kaser hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche, sanofi-aventis, Servier, Takeda. Y.\u00a0Winhofer-St\u00f6ckl hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Sanofi Aventis, AstraZeneca, Novartis, Eli Lilly. L.\u00a0Kazemi-Shirazi hat Honorare von MSD, AbbVie, Ferring, MerckSerono\/Dr Falk, Chiesi, Novartis, Roche, Abbott, Phadia Austria\/Thermo Fisher Scientific und CSL-Behring sowie nicht-finanzielle Unterst\u00fctzung von Mylan, Abbott, MSD, Gilead, MerckSerono\/Dr Falk, Pfizer und Novartis erhalten. S.\u00a0E. Hofer hat von folgendem Unternehmen, das auch f\u00f6rderndes Mitglied der \u00d6DG ist, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Eli Lilly. H.\u00a0Brath hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Abbott Diabetes Care, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Medtronic, MedMedia, MSD, Novartis, Novo Nordisk, Sanofi, Servier. H.\u00a0Sourij hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Amgen, AstraZeneca, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, sanofi-aventis, Takeda. G.\u00a0Vila und H.\u00a0Abrahamian geben an, dass kein Interessenskonflikt besteht. M.\u00a0Riedl hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: AstraZeneca, Eli Lilly, Novo Nordisk, Novartis, Medronic, sanofi-aventis und Takeda sowie vom B\u00fcrgermeisterfond der Stadt Wien Proj.Nr.: 9073. R.\u00a0Weitgasser hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Abbott, Allergan, AstraZeneca, Boehringer-Ingelheim, Dexcom, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Roche, sanofi-aventis, Servier, Takeda. M.\u00a0Resl hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Boehringer Ingelheim, Eli Lilly, Novo Nordisk, sanofi-aventis, Amgen. M.\u00a0Clodi hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, sanofi-aventis, Servier, Takeda. A.\u00a0Luger hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Novo Nordisk, Eli Lilly, Sanofi, Boehringer Ingelheim, MSD, Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}